Washington § 70.225.070 Requirements for test sites in the prescription monitoring program.

Washington Statutes

§ 70.225.070 — Requirements for test sites in the prescription monitoring program.

Washington § 70.225.070

Title 70PUBLIC HEALTH AND SAFETY

Ch. 70.225PRESCRIPTION MONITORING PROGRAM

This text of Washington § 70.225.070 (Requirements for test sites in the prescription monitoring program.) is published on Counsel Stack Legal Research, covering Washington primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

Wash. Rev. Code § 70.225.070 (2026).

Text

(1)Test sites that may receive access to data in the prescription monitoring program under RCW 70.225.040 must be:

(a)Licensed by the department as a test site under chapter 70.42 RCW; and

(b)Certified as a drug testing laboratory by the United States department of health and human services, substance abuse and mental health services administration.

(2)Test sites may not:

(a)Charge a fee for accessing the prescription monitoring program;

(b)Store data accessed from the prescription drug monitoring program in any form, including, but not limited to, hard copies, electronic copies, or web/digital based copies of any kind. Such data may be used only to transmit to those entities listed in *RCW 70.255.040 (3)(a). *Reviser's note: The reference to RCW 70.255.040 appears to be errone

Free access — add to your briefcase to read the full text and ask questions with AI

(1) Test sites that may receive access to data in the prescription monitoring program under RCW 70.225.040 must be:

(a) Licensed by the department as a test site under chapter 70.42 RCW; and

(b) Certified as a drug testing laboratory by the United States department of health and human services, substance abuse and mental health services administration.

(2) Test sites may not:

(a) Charge a fee for accessing the prescription monitoring program;

(b) Store data accessed from the prescription drug monitoring program in any form, including, but not limited to, hard copies, electronic copies, or web/digital based copies of any kind. Such data may be used only to transmit to those entities listed in *RCW 70.255.040 (3)(a).

*Reviser's note: The reference to RCW 70.255.040 appears to be erroneous. RCW 70.225.040 was apparently intended.